From 1 October 2021 the Australian Government announced people aged 60 and over can access any brand of COVID-19 vaccine, including the Comirnaty (Pfizer) or Spikevax (Moderna) vaccines, at all vaccination sites, regardless of where they live.
people aged 18+ can access any COVID-19 vaccine (Pfizer, Moderna and Vaxzevria (AstraZeneca)); and
people aged 12+ can access the Moderna or Pfizer vaccines.
It is important that high priority and vulnerable cohorts continue to be prioritised for vaccination appointments where possible, such as home care workers, disability support workers and Aboriginal and Torres Strait Islander people, to access a COVID-19 vaccine. See Department of Health statement.
Invalid COVID-19 vaccine doses
New ATAGI clinical guidance is available on the use of an additional COVID-19 vaccine dose as a replacement dose for an invalid dose in specified scenarios of schedule deviation or vaccine administration errors, including:
Giving a replacement dose if a second COVID-19 vaccine dose was given at less than 14 days after the first dose
Giving a replacement dose for specified vaccine administration errors resulting in under-dosing
This clinical guidance does not pertain to recommendations for a third or booster dose after completion of the valid two-dose primary course according to an acceptable schedule.
Temporary medical exemptions for COVID-19 vaccines
There are very few situations where a vaccine is contraindicated and as such, medical exemption is expected to be rarely required. ATAGI have developed guidance for providers on acute major medical conditions that warrant a temporary medical exemption relevant for COVID-19 vaccines.
Temporary medical exemptions can only be completed by eligible health professionals utilising their Medicare provider number, and can be recorded on the Australian Immunisation Register (AIR) either by:
An AIR Immunisation History Statement displays all vaccinations or medical contraindications and authorised exemptions, including COVID-19, that have been reported to the Australian Immunisation Register. There is no longer any need to use the NSW Health Medical Contraindication form.
Recognition of overseas COVID-19 vaccines
Following assessment to determine the protection offered by vaccines against infection and serious illness, TGA’s initial advice is that Coronavac (Sinovac) and Covishield (AstraZeneca/Serum Institute of India) vaccines be considered ‘recognised vaccines’ for incoming international travellers to be regarded as appropriately vaccinated.
COVID-19 vaccines which have been granted provisional approval in Australia – Pfizer (Comirnaty), AstraZeneca (Vaxzevria), Moderna (Spikevax) and COVID-19 Vaccine Janssen are also recognised for incoming travellers.
At this point in time, TGA has received insufficient data to reach a conclusion as to the protection offered by BIBP-CorV (Sinopharm), Covaxin (Bharat Biotech), Sputnik V (Gamaleya Institute), and Convidecia (CanSino). These vaccines could be recognised in the coming weeks or months as more data becomes available. See TGA statement.
Children and COVID-19 FAQs
Children aged 12 years and older are recommended to get COVID-19 vaccine and the vaccination program for this age group is underway in Australia. NCIRS has answered some of the most frequently asked questions about COVID-19 in children, vaccines available in Australia, vaccine safety and schooling. The FAQs are available on the NCIRS website.
COVID-19 vaccine safety data for people aged 12 to 19
New COVID-19 vaccine safety data from AusVaxSafety has shown adolescents aged 12–19 years are reporting similar short-term vaccine side effects to those reported by older Australians. AusVaxSafety has received more than 150,000 completed day 3 safety surveys from adolescents aged 12–19 years who received their COVID-19 vaccine and to date, the data analysis has not detected any safety signals for this age group.
Authentication file access to the Australian Immunisation Register (AIR) closed on 30 September 2021 for all providers. A Provider Digital Access (PRODA) account is required to access the AIR via the Health Professionals Online Services (HPOS) portal from this date onward. Instructions for health professionals and medical practices to set up AIR access can be found here.
COVID-19 live stream update for GPs
Join the latest COVID-19 vaccine live stream update for GPs. The panel will provide latest key updates and answer participants’ questions live about the COVID-19 vaccine rollout. Get involved by submitting questions and comments!
Register here for upcoming NCIRS webinar: Weighing up the benefits and risks of COVID-19 vaccination: a focus on safety. Consider the risks and benefits of COVID-19 vaccination and learn strategies for discussions to support your patients, friends and family in making decisions.
Date and time: Wednesday 13 October 2021, 12.30 pm – 2.00 pm AEDT
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
Continuing Professional Development (CPD) annual requirements Below is a snapshot of the continuing professional development (CPD) requirements for doctors, these include annual requirements of: completion of a Professional Development Plan 50 hours CPD each year, split across a range of activities: 25 hours – reviewing performance and measuring outcomes (with five hours minimum…
CESPHN’s Annual Report 2022-23 is now live Central and Eastern Sydney PHN has released its Annual Report 2022-23. The Annual Report is a summary of the key achievements and highlights for the PHN over the financial year. It is split into Improving Care Integration, Improving Practice and Commissioning Services to…